• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA approves MicroTransponder’s stroke rehab neurostim system

FDA approves MicroTransponder’s stroke rehab neurostim system

August 27, 2021 By Sean Whooley

MicroTransponder vagus nerve trial
(Image courtesy of MicroTransponder)

The FDA announced today that it approved the MicroTransponder Vivistim paired VNS system for chronic ischemic stroke rehabilitation.

MicroTransponder designed its Vivistim System as a first-of-its-kind, drug-free rehabilitation system for treating moderate to severe upper extremity motor deficits associated with chronic ischemic stroke using vagus nerve stimulation, according to an FDA news release.

Vivistim electrically stimulates the vagus nerve to reduce deficiencies in upper limb and extremity motor function and to improve patients’ ability to move their arms and hands. An implantable pulse generator is implanted just under the skin in the patient’s chest with a lead wire that leads up to electrodes placed on the left side of the neck where the vagus nerve is.

Along with the implantable components, clinician software on a laptop and a wireless transmitter are used by a healthcare provider to manage a patient’s rehabilitation through settings such as amplitude, frequency and pulse width while also recording stimulation history, movements and information about the implant.

The platform, a prescription device, may be used in both clinical and at-home settings to provide VNS. The approval came on the back of a 108-patient study across 19 clinical sites in the U.S. and United Kingdom. Measuring effectiveness through the Upper Extremity Fugl-Meyer Assessment (FMA-UE), patients receiving Vivistim treatment averaged a score increase of five points, while the control group (only receiving a very low level of VNS) averaged an increase of 2.4 points.

Additionally, 47.2% in the treatment group improved by six or more points at 90 days post-therapy, while just 23.6% did so in the control group.

“People who have lost mobility in their hands and arms due to ischemic stroke are often limited in their treatment options for regaining motor function,” acting director of the FDA’s Center for Devices and Radiological Health’s Office of Neurological and Physical Medicine Devices Dr. Christopher M. Loftus said in the release. “Today’s approval of the Vivistim Paired VNS System offers the first stroke rehabilitation option using vagus nerve stimulation. Used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke.”

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Implants, Neurological, Neuromodulation/Neurostimulation, Regulatory/Compliance Tagged With: FDA, MicroTransponder Inc.

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy